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Contraction in the mammalian heart is controlled by the intracellular Ca2+ concentration
as it is in all striated muscle, but the heart has an additional signaling system that
comes into play to increase heart rate and cardiac output during exercise or stress.
β-adrenergic stimulation of heart muscle cells leads to release of cyclic-AMP and the
activation of protein kinase A which phosphorylates key proteins in the sarcolemma,
sarcoplasmic reticulum and contractile apparatus. Troponin I (TnI) and Myosin Binding
Protein C (MyBP-C) are the prime targets in the myofilaments. TnI phosphorylation
lowers myofibrillar Ca2+-sensitivity and increases the speed of Ca2+-dissociation and
relaxation (lusitropic effect). Recent studies have shown that this relationship between
Ca2+-sensitivity and TnI phosphorylation may be unstable. In familial cardiomyopathies,
both dilated and hypertrophic (DCM and HCM), a mutation in one of the proteins of the
thin filament often results in the loss of the relationship (uncoupling) and blunting of the
lusitropic response. For familial dilated cardiomyopathy in thin filament proteins it has been
proposed that this uncoupling is causative of the phenotype. Uncoupling has also been
found in human heart tissue from patients with hypertrophic obstructive cardiomyopathy
as a secondary effect. Recently, it has been found that Ca2+-sensitizing drugs can promote
uncoupling, whilst one Ca2+-desensitizing drug Epigallocatechin 3-Gallate (EGCG) can
reverse uncoupling. We will discuss recent findings about the role of uncoupling in the
development of cardiomyopathies and the molecular mechanism of the process.
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INTRODUCTION
The heart has a unique system for rapidly and precisely adjusting
cardiac output to meet the demands put upon it. The rhyth-
mic contraction and relaxation of heart muscle is due to the
rise and fall of sarcoplasmic calcium ion (Ca2+) concentration
under neural control. Contraction is initiated by Ca2+ release
from the sarcoplasmic reticulum via the Ryanodine receptor and
is terminated by Ca2+-uptake by the ATP-powered sarcoplas-
mic Ca2+ pump (SERCA). Ca2+ binds to troponin C (TnC), the
Ca2+ receptor of the contractile apparatus to switch on contrac-
tile interactions between actin and the myosin motor protein in
the thick filaments (Gordon et al., 2000; Macleod et al., 2010).
Independently of this Ca2+-switch, the speed and force of con-
traction is modulated in a graded way by changing the inotropic
state of muscle. The inotropic state is largely controlled by the
sympathetic system that releases β-adrenergic agonists at nerve
endings and into the circulation from the adrenal glands. These
bind to and activate β1 receptors on the cardiomyocyte surface
and initiate a cascade leading to increased intracellular cyclic
AMP concentrations which in turn activate the cyclic AMP
dependent protein kinase (PKA) (Macleod et al., 2010). PKA
phosphorylates several proteins in the sarcolemma, sarcoplas-
mic reticulum and the contractile apparatus, thus regulating
their activity. The combined result of the action of PKA is a
co-ordinated increase in cardiac output due to increased heart
rate (chronotropy) increased force of contraction (inotropy) and
increased rate of relaxation (lusitropy) (Layland et al., 2005).
PKA phosphorylates Myosin Binding Protein-C (MyBP-C)
and troponin I (TnI) within the cardiac myofibril. TnI is the
inhibitory component of the trimeric troponin molecule that
makes up the Ca2+-switch of the contractile apparatus. TnI binds
to TnC when Ca2+ is bound to TnC, whilst in the absence of
Ca2+, the C-terminus of TnI is released and is able to interact with
actin and tropomyosin to inhibit the thin filament’s interaction
with the motor protein, myosin. Thus, the interactions of TnC
with TnI and Ca2+ are crucial for the Ca2+ control of muscle.
Early studies showed that β-adrenergic stimulation of contraction
was associated with enhanced phosphorylation of TnI (England,
1976; Solaro et al., 1976), that TnI was bis-phosphorylated at ser-
ines 22 and 23 in the cardiac-specific N-terminal extension by
PKA (Mittmann et al., 1990; Al-Hillawi et al., 1995; Ayaz-Guner
et al., 2009) and that the primary effect of phosphorylation of TnI
in vitro was reduced Ca2+-sensitivity and faster dissociation of
Ca2+ from TnC (Solaro et al., 1976; Robertson et al., 1982; Zhang
et al., 1995; Dong et al., 2007). This can cause an increase in the
rate of relaxation (lusitropic response) which is essential when
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heart rate is increased (Kentish et al., 2001; Layland et al., 2005).
Transgenic mouse studies have demonstrated the physiological
importance of TnI phosphorylation since mice with unphospho-
rylatable TnI have a blunted response to β-adrenergic stimulation
and this leads to an enhanced susceptibility to the development
of heart failure under stress (Fentzke et al., 1999; Pi et al., 2002;
Yasuda et al., 2007).
Over the last 10 years it has become evident that the modu-
lation of myofilament Ca2+-sensitivity by TnI phosphorylation
is quite a labile system and that mutations associated with car-
diomyopathies in particular, can lead to disruption of the system.
This was first noted with mutations in TnI that caused hyper-
trophic cardiomyopathy (HCM) (Deng et al., 2001, 2003) but
its physiological significance was uncovered by studies on dilated
cardiomyopathy (DCM) (Dyer et al., 2007, 2009; Memo et al.,
2013). DCM is a major cause of heart failure in humans and a
substantial proportion of cases of DCM are inherited. Mutations
in the thin filament proteins [actin, tropomyosin, troponin T
(TnT), TnI, and TnC] that are associated with familial DCM
have been studied particularly closely (reviewed in Chang and
Potter, 2005; Morimoto, 2008; Marston, 2011). By studying iso-
lated thin filaments with the quantitative in vitro motility assay
(IVMA) it was found that in all of these DCM-causing muta-
tions the myofilament Ca2+-sensitivity is independent of the level
of TnI phosphorylation. Therefore, by analogy with the S22/23A
transgenic mice, it was proposed that this uncoupling was nec-
essary and sufficient to cause the DCM phenotype (Memo et al.,
2013).
In this review we show that “uncoupling” of TnI phospho-
rylation from changes in Ca2+-sensitivity is a widespread phe-
nomenon with significant implications for the understanding of
heart disease and its treatment.
METHODOLOGY
PHOSPHORYLATION MEASUREMENT
As there is a link between troponin (Tn) phosphorylation
and Ca2+-sensitivity in cardiac muscle, measurement of tro-
ponin I (TnI) phosphorylation levels in situ is very important.
Quantitative methods such as Top-down mass spectrometry and
phosphate affinity SDS-PAGE has clearly established that serines
22 and 23 are the main amino acids phosphorylated in native
heart tissue in rats, mice or humans (Zabrouskov et al., 2008;
Ayaz-Guner et al., 2009; Marston and Walker, 2009; Messer et al.,
2009; Sancho Solis et al., 2009; Wang et al., 2012) (these are often
numbered 23 and 24 according to the coding sequence, however
the N terminal methionine is missing in all mature TnI in heart
tissue). The first quantitative studies used non-equilibrium pH
gradient electrophoresis in 1 or 2D (Ardelt et al., 1998; Kobayashi
et al., 2005). Measurement of phosphorylation became much
easier with the introduction of specific methods to detect phos-
phoproteins using the phosphoprotein gel stain, Pro-Q Diamond
(Steinberg et al., 2003) or antibodies to phosphorylated Tn (Al-
Hillawi et al., 1998; Haworth et al., 2004). This methodology
has been widely adopted, but has its limitations, since to be
quantitative it requires the use of an external standard, which
may introduce systematic errors (Figure 1A) (Messer et al., 2007;
Zaremba et al., 2007).
Thus, to overcome this, we developed the use of phosphate
affinity SDS-PAGE which was first developed by the Kinoshita
group (Kinoshita et al., 2006). Phos-Tags are Mn2+-dependent
specific chelators of phosphoproteins, when added to standard
SDS-PAGE, phosphoproteins are retarded in proportion to the
number of phosphates per mole of protein (Messer et al., 2009).
Thus, unphosphorylated, monophosphorylated and bisphospho-
rylated species of phosphoproteins can be separated (Figure 1B).
We have used Phos-Tags in conjunction with a specific car-
diac TnI antibody to accurately measure phosphorylation levels
in myofibrillar extracts from human heart tissue. The advan-
tage of phosphate affinity SDS-PAGE is that it permits rapid
identification and direct quantification of the mono and bis-
phosphorylated TnI.
All the methods for measuring Ser22/23 phosphorylation in
intact tissue give similar results: flash-frozen mouse or rat heart
yield a phosphorylation level of 1–1.5mol Pi/ mol TnI with up to
40% of TnI being the bis-phosphorylated species, whilst human
donor heart samples have 1.5–2mols Pi/mol TnI with up to 60%
of bis-phosphorylated species. These types of samples have been
widely used in the study of the role of TnI phosphorylation
in modulating muscle regulation, however there is still contro-
versy as to whether these samples are actually representative of
the “normal” heart (Jweied et al., 2007; Marston and Detombe,
2008).
In contrast, pathological samples from hearts transplanted for
idiopathic dilated cardiomyopathy or septal myectomies from
patients with hypertrophic obstructive cardiomyopathy (HOCM)
generally have a low level of phosphorylation (0.1–0.4mols
Pi/mol TnI) (VanDer Velden et al., 2003;Messer et al., 2007, 2009;
Zaremba et al., 2007; Ayaz-Guner et al., 2009; Hamdani et al.,
2009; Jacques et al., 2009; Bayliss et al., 2012b).
MANIPULATION OF TnI PHOSPHORYLATION LEVELS
To investigate the relationship between TnI phosphorylation and
myofilament Ca2+-sensitivity, the Ca2+-sensitivity needs to be
compared with phosphorylated and unphosphorylated Tn, thus
the phosphorylation levels need to be manipulated. Initial in vitro
work used Tn reconstituted from recombinant subunits expressed
in E.coli; TnI could then be readily phosphorylated with PKA cat-
alytic subunit. For transgenic mouse studies, unphosphorylatable
TnI could be overexpressed (either slow skeletal TnI in place of
cardiac or mutant TnI with Ser 22/23 mutated to alanine Fentzke
et al., 1999; Pi et al., 2002; Yasuda et al., 2007). Phosphorylated
TnI could be simulated with Ser 22/23 mutated to aspartic acid
(Dohet et al., 1995; Mamidi et al., 2012). The first studies of
native human heart Tn in IVMA or skinned myocyte contrac-
tility compared donor and failing human heart muscle samples,
since they had high and low levels of phosphorylation respectively
(Van Der Velden et al., 2003; Messer et al., 2007). However, it
was not certain whether differences in Ca2+-sensitivity observed
(Figure 2A) were due to the different phosphorylation levels or
other disease-related factors.
Ideally, one should be able to study the same sample at dif-
ferent phosphorylation levels. This can be done by dephospho-
rylation or phosphorylation. The phosphorylation level of Tn
isolated from heart tissue may be reduced by treatment with a
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FIGURE 1 | SDS-PAGE analysis of myofibrillar proteins and
phosphoproteins. (A) Myofibril fraction of heart muscle separated by
SDS-PAGE and stained successively with Pro-Q Diamond phosphoprotein
stain and SYPRO Ruby total protein stain. Left, NTG and ACTC E99K
mouse heart myofibrils (38 weeks male). Right, donor and ACTC E99K
heart sample 2 myofibrils (Song et al., 2011). The TnI band is strongly
stained together with MyBP-C, TnT and MLC-2. (B) Phosphate affinity
SDS-PAGE analysis of TnI phospho-species. Left, comparison of TnI
phosphorylation in 21-week-old female ACTC E99K and NTG mouse
myofibrils. Right, comparison of TnI phosphorylation in myofibrils from
ACTC E99K sample 2, donor heart and a typical interventricular septum
sample from a patient with hypertrophic obstructive cardiomyopathy
(HOCM) (Song et al., 2011). All samples show a high level of
phosphorylation, except for the failing heart sample.
phosphatase (shrimp alkaline phosphatase has proved to be the
most reliable enzyme) or increased by PKA treatment (Bayliss
et al., 2012b). PKA treatment has been used successfully for many
years to increase the level of phosphorylation of isolated myocytes
or skinned muscle strips (Hamdani et al., 2009; Kooij et al., 2010)
but dephosphorylation is not usually successful, either there is
inadequate reduction in phosphorylation level or the enzyme
preparations cause degradation of the muscle. To dephospho-
rylate heart muscle in laboratory animals a different method
may be used. For instance, mice can be treated with Propranolol
(8mg/kg) to block β1-adrenoreceptors and deactivate PKA to
reduce phosphorylation levels of PKA substrates including Tn
and MyBP-C (Bailin, 1979; Wang et al., 2011; Vikhorev et al.,
2013).
NORMAL RELATIONSHIP BETWEEN TnI PHOSPHORYLATION
AND Ca2+-REGULATION
It was established, soon after the discovery of troponin I (TnI)
phosphorylation, that phosphorylation of troponin (Tn) modu-
lates Ca2+-regulation by Tn by reducing the Ca2+-sensitivity and
increasing the force or crossbridge turnover rate at maximally
activating Ca2+ concentrations (Ray and England, 1976; Bailin,
1979; Mope et al., 1980). The magnitude of the Ca2+-sensitivity
shift has been consistently been measured in the 2–3-fold range.
It has been demonstrated that the reduced Ca2+-sensitivity is due
to an increase in the rate of Ca2+-dissociation from Tn in the
thin filaments (Robertson et al., 1982; Zhang et al., 1995; Dong
et al., 2007), thereby providing a mechanism for the lusitropic
(faster relaxation) response to β-adrenergic stimulation. Two
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FIGURE 2 | (A) Ca2+-regulation of thin filament motility by non-failing (donor)
and failing heart troponin. Thin filament motility was measured by motility
assay over a range of [Ca2+] in paired cells. The percentage of filaments
motile is plotted as a function of [Ca2+] for a representative experiment. In
blue lines and points, non-failing thin filaments, red lines and open points,
failing thin filaments. TnI phosphorylation levels are shown in Figure 1B. The
points ± s.e.m. are the mean of four determinations of percentage motile
measured in one motility cell. The curves are fits of the data to the Hill
equation (Messer et al., 2014). (B) Relationship between EC50 for
Ca2+-activation of thin filaments and TnI bisphosphorylation. EC50 for thin
filaments containing human heart Tn was plotted against the level of TnI
bis-phosphorylation. EC50 was measured by IVMA and bis-phosphorylation of
TnI (approximates to phosphorylation at Ser22 and 23) was measured by
phosphate affinity SDS-PAGE. D, donor heart Tn, XI donor Tn with TnI
exchanged, XI:D mixed donor and cTnI-exchanged donor, XI P PKA-treated
cTnI-exchanged donor, D P PKA treated donor heart Tn. The gray band
corresponds to the phosphorylation level range of human donor and
wild-type mouse Tn, see Figure 1B (Memo et al., 2013).
recent studies have directly shown the relationship between phos-
phorylation and Ca2+-sensitivity. A study by Messer et al. used
the in vitromotility assay (IVMA)with isolated human cardiac Tn
in reconstituted thin filaments. By manipulating the level of Tn
phosphorylation and then measuring the level using phosphate
affinity SDS-PAGE (Phos-Tags) (Messer et al., 2009), a consistent
relationship between phosphorylation level and Ca2+-sensitivity
was found (Memo et al., 2013) (Figure 2B). A similar study by
Kooij et al. measured the force in individual cardiomyocytes and
found a similar relationship between TnI phosphorylation at
Ser22/23 and Ca2+-sensitivity (Kooij et al., 2010). A reduced level
of cTnI phosphorylation has been observed in end-stage failing
hearts and this correlates with the increased Ca2+-sensitivity seen
when failing hearts were compared to donor hearts (Figure 2A)
(Wolff et al., 1995; Bodor et al., 1997; Van Der Velden et al., 2003;
Messer et al., 2007).
THE DISCOVERY OF UNCOUPLING IN FAMILIAL
CARDIOMYOPATHIES
Initial investigations into the functional consequences of car-
diomyopathy mutations did not consider the role of TnI phos-
phorylation, but when this was investigated, uncoupling was
immediately apparent. Uncoupling was first reported in a series of
studies from Kornelia Jaquet’s laboratory. Deng et al. studied the
cTnI HCM mutation R145G and compared phosphorylated and
unphosphorylated recombinant R145G mutant Tn in reconsti-
tuted thin filaments regulating actomyosin ATPase. The authors
found that the shift in pCa50 due to bisphosphorylation, observed
with wild-type Tn, was not statistically significant (Deng et al.,
2001). Later, two other HCM-causing mutations in cTnI, G203S,
and K206Q, were also shown to uncouple, although the effect
with G203S was only partial (Deng et al., 2003). A study on
the cTnI HCM mutation R21C found that the Ca2+-sensitivity
decrease due to PKA phosphorylation was smaller when com-
pared to wild-type (Gomes et al., 2005). A similar study on the
cTnC HCM mutation L29Q also found that the Ca2+-sensitivity
(measured by both actomyosin ATPase activity and IVMA) was
not affected by PKA phosphorylation of cTnI (Schmidtmann
et al., 2005). In fact, this study was the first to suggest that the
mutation hindered the transduction of the phosphorylation sig-
nal from TnI to TnC. Dong et al. have investigated the effects of
cTnI phosphorylation on the kinetics of Ca2+ regulation of Tn
both in wild-type andmutant Tn (Dong et al., 2007). The authors
not only looked at the HCM-causing L29Q mutation in TnC but
also the DCM-causingmutation TnCG159D and found that both
mutations inhibited the ability of PKA phosphorylation of cTnI
to reduce Ca2+-sensitivity and speed up Ca2+ dissociation (Dong
et al., 2008).
The DCM-causing TnC G159D mutation is one of the best
characterized clinically (Mogensen et al., 2004; Kaski et al.,
2007) and the uncoupling phenomenon was also investigated
in two further studies. Biesiadecki et al. reported that the
cTnC G159D mutation, exchanged into skinned mouse car-
diac fibers, had no direct effect on the myofilament response
to Ca2+ but it blunted the phosphorylation-dependent change
in Ca2+ sensitive tension development without altering cross-
bridge cycling rate (Biesiadecki et al., 2007). Dyer et al., inves-
tigated Tn containing the TnC G159D mutation in mutant Tn
isolated from an explanted heart muscle sample in compar-
ison with donor heart Tn using IVMA and similarly found
that, unlike donor heart, Ca2+-sensitivity and maximum sliding
speed of thin filaments containing G159D Tn were not sensitive
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to changes in TnI phosphorylation levels (Dyer et al., 2007,
2009).
These seminal studies on uncoupling investigated mutations
in the regions of TnI and TnC that could be directly involved
in the phosphorylation-dependent interaction that modulates
Ca2+-sensitivity. However, subsequent studies showed that muta-
tions in any protein of the thin filament can induce uncoupling,
including actin (ACTC E361G and E99Kmutations) tropomyosin
(E40K, E54K, and D230N mutations) and troponin T (TnT) (4
mutations recorded to date) in addition to 5 mutations in cTnC
and 5 mutations in TnI. The currently known mutations causing
uncoupling are summarized in Table 1. Thus, uncoupling may
be induced by indirect allosteric effects of mutations anywhere
within the thin filament and uncoupling seems to be correlated
with mutations identified as causing cardiomyopathies.
UNCOUPLING AS A PRIMARY CAUSE OF FAMILIAL DILATED
CARDIOMYOPATHY
The recent study by Memo et al. (2013) investigated the uncou-
pling phenomenon in thin filaments containing a wide range
of mutations associated with familial DCM, using the IVMA
to measure myofilament Ca2+-sensitivity. It was found that
when TnI was fully phosphorylated, the mutations had dif-
ferent effects on Ca2+-sensitivity of thin filaments compared
to non-failing; some increased Ca2+-sensitivity (cTnT R141W
and K210, cTnI3 K36Q and α-Tropomyosin E40K), some
decreased it (α-Tropomyosin D230N, cTnC G159D) whereas for
α-actin E361G and α-Tropomyosin E54K there was no change in
Ca2+-sensitivity. This confirmed that the simple hypothesis that
Ca2+-sensitivity is always reduced by DCM-causing mutations,
that we and others had proposed, is no longer tenable (Chang
and Potter, 2005; Mirza et al., 2005;Morimoto, 2008). In contrast,
when the Ca2+-sensitivity of thin filaments containing phospho-
rylated and unphosphorylated TnI were compared, it was found
that incorporation of any of these mutations caused uncoupling
(Memo et al., 2013) (Figure 3).
Another study found uncoupling in rare TnC variants identi-
fied in DCM: cTnC Y5H, M103I, and I148V either decreased or
abolished the effects of PKA phosphorylation on Ca2+-sensitivity
(Pinto et al., 2011). Since all the known DCM-causing muta-
tions in thin filament proteins have now been shown to cause
uncoupling, whilst having a very variable effect on absolute Ca2+-
sensitivity and no DCMmutation has been demonstrated to have
normal coupling, there is a strong case for uncoupling to be
causative of DCM due to mutations of thin filament compo-
nents. Thus, a blunting of the heart’s response to β-adrenergic
stimulation seems to be necessary and sufficient to generate the
DCMphenotype. Mechanisms and physiological consequences of
uncoupling are discussed in detail later in this review.
UNCOUPLING IS A COMMON FEATURE OF
CARDIOMYOPATHIES
Uncoupling is widespread, not only is it observed with muta-
tions that cause familial DCM, it is also observed with muta-
tions that cause hypertrophic cardiomyopathy (HCM). TheHCM
phenotype has been generally thought to be due to mutations
Table 1 | Mutations that have been reported to cause uncoupling.
Mutation Effect of mutation on Measurement Publication
Ca2+-sensitivity method
DCM
ACTC E361G No difference IVMA Song et al., 2010; Memo et al., 2013
TPM1 E54K No difference IVMA Memo et al., 2013
TPM1 E40K Decrease IVMA Memo et al., 2013
TPM1 D230N Increase IVMA Memo et al., 2013
TNNC1 G159D Increase IVMA/Ca binding Biesiadecki et al., 2007; Dong et al., 2008; Dyer et al., 2009;
Memo et al., 2013
TNNC1 Y5H Decrease Skinned fiber Pinto et al., 2011
TNNC1 M103I Decrease Skinned fiber Pinto et al., 2011
TNNC1 I148V Decrease Skinned fiber Pinto et al., 2011
TNNT2 K210 Decrease IVMA/Skinned fiber Du et al., 2007; Inoue et al., 2013; Memo et al., 2013
TNNT2 R141W Decrease IVMA Memo et al., 2013
TNNI3 K36Q Decrease IVMA/ATPase Carballo et al., 2009; Memo et al., 2013
HCM
ACTC E99K Increase IVMA Song et al., 2011
TPM1 E180G Increase Skinned fiber Alves et al., 2014
TNNC1 L29Q Increase Ca binding/ATPase Schmidtmann et al., 2005; Dong et al., 2008; Li et al., 2013
TNNT2 K280N Increase IVMA Bayliss et al., 2012a
TNNI3 R145G Increase IVMA/ATPase Deng et al., 2001
TNNI3 R21C Increase Skinned fiber Gomes et al., 2005; Wang et al., 2011
TNNI3 G203S Increase ATPase/IVMA Deng et al., 2003
TNNI3 K206Q Increase ATPase/IVMA Deng et al., 2003
TNNT2 R92W Increase Cardiac myocytes Guinto et al., 2009
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FIGURE 3 | Demonstration of uncoupling due to DCM and HCM
mutations and secondary to HOCM. Thin filament motility was measured
by motility assay over a range of [Ca2+] in paired cells. The percentage of
filaments motile is plotted as a function of [Ca2+] for a representative
experiment. Solid lines and points, phosphorylated thin filaments, dotted line
and open points, unphosphorylated thin filaments (obtained by phosphatase
treatment). The points ± s.e.m. are the mean of four determinations of
percentage motile measured in one motility cell. The curves are fits of the
data to the Hill equation. (A) Natively phosphorylated and unphosphorylated
human donor heart Tn with DCM related α- tropomyosin D230N (100%) and
rabbit skeletal muscle α-actin (Memo et al., 2013). (B) Natively
phosphorylated and unphosphorylated human donor heart Tn with
exchanged recombinant HCM related TnT K280N, human heart tropomyosin
and rabbit skeletal muscle α-actin (Messer et al., 2014). (C) Thin filaments
containing Tn from a HOCM heart (0.1mol Pi/mol TnI) or protein kinase
A-treated HOCM heart Tn (1.6mol Pi/mol TnI) (Bayliss et al., 2012b). (D) EC50
of phosphorylated Tn relative to EC50 of unphosphorylated Tn is plotted for
wild-type thin filaments and thin filaments containing DCM and HCM-causing
mutations. Error bars show s.e.m. of up to 7 replicate comparative
measurements (Memo et al., 2013; Messer et al., 2014).
increasing myofilament Ca2+-sensitivity, but it is possible that
uncoupling is also characteristic of HCM (Marston, 2011). In
addition to the early reports of HCM-causing TnI mutations,
described above, uncoupling has also been demonstrated in
cTnT R92W (Guinto et al., 2009), cTnT K280N (Messer et al.,
2012), α-Tropomyosin E180G (Alves et al., 2014), cardiac actin
E99K (Song et al., 2011) and cTnI R21C (Wang et al., 2011)
(see Table 1). The situation is less clear-cut in studies using
human heart samples; Sequeira et al. (2013) reported that some
HCM mutations were uncoupled, but others showed a par-
tial decrease in Ca2+-sensitivity when phosphorylated indicat-
ing that uncoupling is not necessarily an all-or-nothing effect
in human heart but may be graded. Relevant to these obser-
vations is the report that in human heart samples the effect
of phosphorylation on EC50 was dependent upon background
phosphorylation levels of other myofilament proteins (Kooij
et al., 2010).
Uncoupling has been demonstrated to occur as a secondary
effect unrelated to any mutation. In the obstructive variant
of HCM (HOCM) the hypertrophied interventricular septum
causes LVOTO (left ventricular outflow tract obstruction) and
pressure overload. Several abnormalities in the contractile pro-
teins in septal tissue from HOCM patients have been observed
including; low phosphorylation levels of TnI and MyBP-C
(Messer et al., 2009; Copeland et al., 2010b), differences in
actin isoform expression (Copeland et al., 2010a) and loss of
function in myosin (Jacques et al., 2008). Most of these abnor-
malities are shared with end-stage failing heart, but the Ca2+-
sensitivity of Tn from HOCM samples, studied by IVMA, was
not as expected from its low TnI phosphorylation level and
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this was found to be due to uncoupling of the relationship
between Ca2+-sensitivity and TnI phosphorylation (Gallon et al.,
2007; Jacques et al., 2008; Bayliss et al., 2012b). Uncoupling
was demonstrated directly by comparing HOCM Tn with PKA-
treated HOCM Tn to bring phosphorylation up to the same
level as donor heart Tn. There was no change in Ca2+-sensitivity
(Figures 3C,D). This uncoupling was independent of the muta-
tion causing HCM and was even observed when no muta-
tion was identified. Exchange experiments were carried out to
identify which component of the Tn complex was responsible
for the uncoupling and the abnormality was shown to be in
TnT, although no covalent modifications were found (Bayliss
et al., 2012b). This uncoupling in HOCM may be related to
the severe pressure overload that patients having myectomy
operations exhibit and therefore it is possible that the uncou-
pling is caused by the pressure overload itself. It would, for
instance, be interesting to look at aortic stenosis samples where
the patients have pressure overload but not HCM (Marston et al.,
2012).
The occurrence of uncoupling in other types of cardiomy-
opathy has not been tested; it is clear that in most cases of
idiopathic DCM, Ca2+-sensitivity is fully coupled to the level
of TnI phosphorylation (Messer et al., 2007). On the other
hand, it is possible that mutations in sarcomeric proteins that
are not part of the contractile apparatus, such as titin or Z-
line proteins, also undergo uncoupling, since these can show
a blunted response to β-adrenergic stimulation in vitro that
is characteristic of uncoupling. Recent studies have shown a
blunted β-adrenergic response in MLP W4R and TCAP KO mice
(Knoell et al., 2010, 2011) and uncoupling could be inferred
from experiments on a mouse model with a titin mutation
(Gramlich et al., 2009).
UNCOUPLING CAN BE INDUCED BY SMALL MOLECULES
AND PHOSPHORYLATION
The key to the modulation of Ca2+-sensitivity by cTnI phos-
phorylation is the interaction of the N-terminal peptide 1–29 of
cTnI with TnC, therefore it may be possible to induce uncou-
pling with small molecules that bind to TnC and change the
Ca2+-sensitivity (Ca2+ sensitizers or desensitizers). Of partic-
ular interest are the Ca2+-sensitizing drugs EMD57033 and
Bepridil (Li et al., 2008). When tested in the IVMA, with
thin filaments containing native human Tn, both these drugs
increased Ca2+-sensitivity by 2–3-fold and at the same time
uncoupled Ca2+-sensitivity from TnI phosphorylation (see
Figure 4A). The effect of these drugs is therefore quite analo-
gous to the effect of many HCM-causing mutations (Table 1,
Figures 3, 4).
In contrast EGCG [(−)-Epigallocatechin 3-Gallate], is a Ca2+-
desensitizer that binds at a site formed by the TnI-TnC complex
and it has been found to enhance the binding of the N terminal
helix1 of TnI to TnC (Robertson et al., 2009; Tadano et al., 2010;
Botten et al., 2013). When tested in the IVMA, with thin filaments
containing native human Tn, EGCG decreased Ca2+-sensitivity
both in wild-type and in DCM-mutant thin filaments and in both
phosphorylated and unphosphorylated filaments, thus preserving
coupling (Figure 4B). Most strikingly it is also capable of restor-
ing coupling to thin filaments containing mutations that induce
uncoupling (Messer et al., 2014).
Another perturbation that can induce uncoupling is phospho-
rylation of troponin subunits. A study by Nixon et al. found
that phosphorylation of cTnI at Ser 150 by AMP-activated pro-
tein kinase (AMPK) increased Ca2+-sensitivity of isolated cardiac
myofibrils. It also blunted the PKA-dependent calcium desensiti-
zation induced by phosphorylation at Ser 22/23 and uncoupled
FIGURE 4 | Effect of Ca2+-sensitizers and desensitizers on coupling in
thin filaments. Thin filament motility was measured by motility assay over
a range of [Ca2+] in paired cells. The percentage of filaments motile is
plotted as a function of [Ca2+] for representative experiments. Solid lines
and points, phosphorylated thin filaments, dotted line and open points,
unphosphorylated thin filaments (obtained by phosphatase treatment). The
points ± s.e.m. are the mean of four determinations of percentage motile
measured in one motility cell. The curves are fits of the data to the Hill
equation. (A) The effect of the Ca2+-sensitizer EMD57033 (EMD). In dark
blue, thin filaments in the absence of EMD and in light blue are thin
filaments in the presence of 30μM EMD (Messer et al., 2014). (B) The
effect of the Ca2+-desensitizer EGCG. In dark blue, thin filaments in the
absence of EGCG and in orange, thin filaments in the presence of 100μM
EGCG (Messer et al., 2014).
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the effects of phosphorylation from β-adrenergic stimulation
(Nixon et al., 2012).
MOLECULAR MECHANISM OF UNCOUPLING
The phosphorylation dependence of cardiac Tn Ca2+ regulation
is due to the interaction of a 30 amino acid N-terminal extension
of TnI, containing the PKA-specific phosphorylation sites at Ser
22 and 23, with cTnC (Solaro et al., 2008).
The N-terminal segment of cTnI interacts with the regulatory
Ca2+-binding loop in the N-terminal lobe of TnC in the unphos-
phorylated state. This affects the cTnC interaction with both the
regulatory Ca2+ and the TnI switch peptide (144–160) (Li et al.,
2008). When TnI is unphosphorylated there is a weak ionic bond
between the N terminal and the regulatory Ca2+-binding EF hand
of TnC (Howarth et al., 2007). When Ser 22 and 23 are phos-
phorylated the binding is further weakened (Keane et al., 1990;
Ferrieres et al., 2000; Ward et al., 2004a,b; Baryshnikova et al.,
2008). Therefore, the unphosphorylated state of TnI is a spe-
cial state, which is destabilized by phosphorylation, resulting in a
lower Ca2+-sensitivity and higher rate of Ca2+ dissociation. Since
the initial interaction is quite weak, the loss of the interaction pro-
duces only a 2–3-fold change in Ca2+-sensitivity and the rate of
Ca2+ dissociation. This appears to be sufficient to generate the
lusitropic effect since heart rate also increases by a maximum of
2–3-fold.
We propose that the unphosphorylated state can also be dis-
rupted by mutations or other alterations in any component of
the thin filament resulting in the same destabilized state for both
phosphorylated and unphosphorylated Tn; in this way uncou-
pling could be considered as a default state in cardiomyopathies
(Liu et al., 2012; Memo et al., 2013).
Recent studies have begun to determine the structure of TnI
in complex with TnC in the phosphorylated and unphosphory-
lated states that forms the basis of the coupling mechanism. X-ray
crystallography has defined the core structure of Tn but mobile
segments, including the N-terminus of TnI, were not present
in the crystal structure (Takeda et al., 2003). NMR studies have
defined the structure of themissing peptides based on their binary
complexes. A best guess structure of the N-terminal peptide con-
formation in the phosphorylated and unphosphorylated states
was proposed by building these structures onto the Tn core struc-
ture (Howarth et al., 2007). Molecular dynamics simulations of
the entire Tn molecule have further refined these structures.
The molecular dynamics simulations indicate a possible struc-
ture of TnI N-terminus interacting with TnC (Gould et al., 2014)
(Figure 5). The most striking feature is that in the presence of
Ca2+, the unphosphorylated N terminus of TnI settles in a posi-
tion looping over the N-terminus of TnC within 50 ns of the start
of simulation. The peptide is mostly very mobile and unstruc-
tured except for 20RRSS24 that was consistently close to TnC for
up to 1μs of simulation. These four amino acids also exhibited
a lower root mean square fluctuation (RMSF) than surround-
ing residues. When the Ser 22 and 23 were phosphorylated in
silico, the two serines become more mobile relative to arginines
20 and 21 suggesting a weakening of their interaction with TnC.
In addition, Ca2+ becomes more exposed to solvent and the
interaction of the “switch peptide” with TnC is altered. Thus,
FIGURE 5 | Modulation of the interaction of TnI Ser 22 and 23 with the
N terminal lobe of TnC by phosphorylation, determined by molecular
dynamics simulations. Average structure after 700 ns simulation for
unphosphorylated Tn, left. The Tn was phosphorylated in silico after 550 ns
of simulation and the average structure after a further 200 ns is shown,
right. The N-terminal lobe of cTnC is shown as spheres with color coding
along the peptide chain as indicated by the sequence below; Ser 69 and Thr
71 are colored according to their atoms (oxygen red, hydrogen white). The
backbone of cTnI N-terminus is shown in blue; Ser 22 and 23 are shown in
yellow in stick representation. Molecular dynamics suggests that with
unphosphorylated Tn there is a close interaction of Ser 22 and 23 with
cTnC Ser 69 and Thr 71 which is much less prominent when
phosphorylated (Gould et al., 2014).
coupling can be accounted for by the formation of a weak ionic
complex between TnC and TnI Ser 22 and 23 that is destabilized
by phosphorylation.
It is interesting to note that when the DCM-causing mutation
K36Q in cTnI was introduced in the presence of Ca2+, the simu-
lation showed that Ser 22 and 23 no longer interacted closely with
cTnC, in accord with our hypothesis that the Ca2+-cTnC-cTnI
N terminus interaction is unique and is destabilized directly by
phosphorylation and also allosterically by mutations and other
perturbations. Molecular dynamics simulations also show that
phosphorylation is associated with long-range conformational
changes in Tn and associated proteins that provides a mecha-
nism for mutations in TnT, tropomyosin and actin to induce
uncoupling (Manning et al., 2011). It should be noted that this
mechanism for uncoupling is the opposite to one proposed by
Biesiadecki et al. (2007) where the DCM mutation TnC G159D
was proposed to stabilize the interaction of Ser 22 and 23 with
cTnC when phosphorylated.
PHYSIOLOGICAL RELEVANCE OF UNCOUPLING
How is uncoupling of the relationship between TnI phospho-
rylation and myofilament Ca2+-sensitivity related to the DCM
phenotype associated with such mutations? We think it is likely
that uncoupling would compromise the heart’s response to β1-
adrenergic stimulation leading to a reduced cardiac reserve.
The effects of cardiomyopathy-causing mutations on the
heart’s response to β-adrenergic agonists have not been routinely
measured. However, the studies of Song et al. on the ACTC
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mutations E361G and E99K investigated this question and clearly
showed that the response to dobutamine stimulation was blunted
(Song et al., 2010, 2011; Marston et al., 2013) (Figure 6). The
effect of adrenergic agonists was tested in several other models
of HCM and DCM (see Table 2) and they all showed blunting of
the response in at least one parameter. It is particularly interest-
ing to note the blunting effect of the muscle LIM protein (MLP)
W4R mutation associated with DCM (Knoell et al., 2010), since
this protein is a component of the Z-line and is not known to have
any function in regulating the contractile apparatus: in this case
the putative uncoupling might be a secondary effect similar to
that seen in myectomy samples. Nguyen et al. found that young,
pre-hypertrophic TNNI3 G203S HCM transgenic mice lacked
the normal physiological response to chronic intense swim-
ming exercise, compatible with a blunted response to adrenergic
stimulation independent of disease phenotype (Nguyen et al.,
2007).
This loss of cardiac reserve is likely to predispose the heart
to failure when under stress. It is notable that most mouse
models of DCM-causing mutations show little or no pheno-
type at rest (ACTC E361G, TNNT2 K210, MYBPC3 knock-in
(KI) (see Table 2) and TTN KI Gramlich et al., 2009), especially
when heterozygous like the patients with these mutations. This
is compatible with the primary defect being in the response to
β-adrenergic stimulation that is absent at rest. Several experi-
ments have addressed this question by exposing transgenic mice
with HCM or DCM-causing mutations to chronic stress by pres-
sure overload (TAC) or by chronic stimulation with isoprenaline
or angiotensin II. In general, they demonstrate that the mutant-
containing mice show earlier and more severe symptoms of
FIGURE 6 | (A) The ACTC E361G mutation blunts the lusitropic, inotropic and
chronotropic response to dobutamine in vivo: mice were examined using a
pressure volume catheter. The dobutamine-induced acceleration of relaxation
(peak rate of relaxation and time constant of relaxation) was significantly
lower in ACTC E361G mice indicating a blunted lusitropic response. The
inotropic response to dobutamine was also blunted in ACTC E361G mice as
indicated by a blunted increase in maximum pressure and the peak rate of
pressure increase. Furthermore, dobutamine-induced increase in heart rate
(chronotropic effect) was also blunted. Taken together with the attenuated
increase in cardiac output these data suggest a significantly diminished
cardiac reserve in ACTC E361G mice in vivo (Wilkinson, 2014). (B) The ACTC
E361G mutation predisposes TG mice to systolic heart failure under chronic
stress: chronic stress was achieved using subcutaneously implanted Alzet
osmotic mini pumps to deliver a 4-week infusion of angiotensin II
(2mg/kgBW/day, in saline). Sham controls received mini pumps carrying
saline only. At the end of the 4-week infusion period the mice were examined
using a pressure volume catheter. The chronic stress treatment evoked
symptoms of systolic heart failure in ACTC E361G mice, characterized by
decreased ejection fraction, cardiac output and maximum rates of contraction
and ejection compared to NTG mice (Wilkinson, 2014).
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Table 2 | Mutations reported to blunt response to β-agonists.
Mutation Measurement method, agonist and
(parameters blunted)
Publication
ACTC E361G Echocardiography and cine MRI
Dobutamine stimulation
(mri: EF, HR,COEcho: wall thickening
and CO)
Song et al., 2010
ACTC E99K Echocardiography
Dobutamine stimulation
(heart rate, wall thickening, and
fractional shortening)
Song et al., 2011
TPM1 E54K Echocardiography
Isoprenaline stimulation (+dP/dt,
−dP/dt)
Rajan et al.,
2007
TNNT2 K210 PV catheter
Isoprenaline stimulation (LVESP)
Du et al., 2007
TNNT2 R173W iPSC myocyte cluster contraction,
noradrenaline stimulation (beating
rate)
Sun et al., 2012
TNNT2 E160 Isolated heart isovolumic pressure
recording,
Dobutamine stimulation (−dP/dt)
Moore et al.,
2013
TNNT2 R92Q Isolated heart isovolumic pressure
recording,
Dobutamine stimulation (SP, +dP/dt,
−dP/dt, DevP)
Javadpour et al.,
2003
TNNT2 I79N Echocardiography,
Isoprenaline stimulation (FS)
Knollmann et al.,
2001
MYBPC3 KI Engineered heart tissue
Isoprenaline stimulation (Force)
Stöhr et al., 2013
MYBPC3 KO PV catheter
Dobutamine stimulation (dP/dt max )
Carrier et al.,
2004
MLP W4R Echocardiography and PV catheter
Adrenaline stimulation (ESV,EDV and
LV contractility)
Knoell et al.,
2010
dilation and heart failure than wild-type. For instance: Wilkinson
applied chronic stress by angiotensin II infusion (2mg/KgBV/da
by osmotic minipumps). After 4 weeks ACTC E361G DCM
mice had significantly lower dP/dtmax, cardiac output and ejec-
tion fraction, compared to NTG (Wilkinson, 2014) (Figure 6).
Similarly Gramlich et al. studied a titin mutation that causes
DCM (TTN 2-bp insertion mutation (c.43628insAT)) (Gramlich
et al., 2009). The authors induced cardiac hypertrophy by a
2-week infusion with angiotensin II. Both wild-type and KI
mice developed cardiac hypertrophy after 1 week. After 2 weeks,
hypertrophy in wild-type animals was further increased, whereas
their heterozygous littermates showed left ventricular dilata-
tion with impaired systolic function and increased myocardial
fibrosis.
Whilst it is recognized that the uncoupling phenomenon pro-
vides a satisfactory molecular mechanism for thin-filament based
mutations that cause DCM, the role of uncoupling in HCM
is not as clear. Since Ca2+-sensitivity has been observed to be
increased 2–3-fold in virtually every HCM mutation investigated
(Marston, 2011), it is likely that this is the primary trigger for
the HCM phenotype and that it dominates over the uncoupling
phenomenon. It is possible that increased Ca2+-sensitivity and
uncoupling are linked properties of thin filaments since the Ca2+-
sensitizers EMD57033 and bepridil are also uncouplers and the
coupling constant is generally greatest when Ca2+-sensitivity is
lowest. It will be very interesting to investigate whether any
HCMmutations (or Ca2+-sensitizers) can be found that increase
Ca2+-sensitivity but do not uncouple.
CLINICAL RELEVANCE OF UNCOUPLING
Uncoupling inevitably leads to blunting of the response to β-
adrenergic agonists but the lack of response to dobutamine is of
course not only due to uncoupling. Heart failure is associated also
with desensitization of β-receptors, such that the activation of
PKA is attenuated, or the activity of phosphatase increased whilst
coupling is intact (Houser andMargulies, 2003; Champion, 2005;
El-Armouche et al., 2007; Messer et al., 2007).
Patient studies from the 80 and 90 s using echocardiogra-
phy showed that IDCM and HCM patients could be classified
into dobutamine responders and non-responders and that the
non-responders have a poor prognosis whilst the responders can
respond to treatment (Borow et al., 1988; Dubois-Randé et al.,
1992; Naqvi et al., 1999) These studies predate the discovery
of mutations in contractile proteins that cause familial DCM
as well as the discovery of uncoupling, but given our current
understanding of FDCM we would predict that the dobutamine
non-responders correspond to those patients with FDCM muta-
tions causing uncoupling and hence presumably the dobutamine
response would be of clinical interest as a potential diagnostic to
distinguish familial DCM from acquired IDCM.
This dichotomy would suggest that different treatments would
be optimum for the two cases. Drugs are available that impact
on β-receptors but so far no drugs act positively on the
TnI-phosphorylation-Ca2+-sensitivity coupling mechanism. Our
recent finding that EGCG is capable of recoupling in vitro,
although it has different effects in vivo (Feng et al., 2012), sug-
gests that specific modulation of the coupling process may be a
viable target for future therapy.
ACKNOWLEDGMENT
This work was supported by grants from The British Heart
Foundation (RG/11/20/29266 and FS/12/29568).
REFERENCES
Al-Hillawi, E., Bhandari, D. G., Trayer, H. R., and Trayer, I. P. (1995). The
effects of phosphorylation of cardiac troponin-I on its interactions with
actin and troponin-C. Eur. J. Biochem. 228, 962–970. doi: 10.1111/j.1432-
1033.1995.tb20347.x
Al-Hillawi, E., Chilton, D., Trayer, I. P., and Cummins, P. (1998). Phosphorylation-
specific antibodies for human cardiac troponin-I. Eur. J. Biochem. 256, 535–540.
doi: 10.1046/j.1432-1327.1998.2560535.x
Alves, M. L., Dias, F. A. L., Gaffin, R. D., Simon, J. N., Montminy, E.M., andWolska,
B. M. (2014). Desensitization of myofilaments to Ca2+ as a therapeutic target
for hypertrophic cardiomyopathy withmutations in thin filament proteins.Circ.
Cardiovasc. Gen. 7, 132–143. doi: 10.1161/CIRCGENETICS.113.000324
Ardelt, P., Dorka, P., Jaquet, K., Heilmeyer, L. M. G., Kortke, H., Korfer, R., et al.
(1998). Microanalysis and distribution of cardiac troponin I phosphospecies in
heart areas. Biol. Chem. 379, 341–347. doi: 10.1515/bchm.1998.379.3.341
Ayaz-Guner, S., Zhang, J., Li, L., Walker, J. W., and Ge, Y. (2009). In vivo phospho-
rylation site mapping in mouse cardiac troponin i by high resolution top-down
electron capture dissociation mass spectrometry: Ser22/23 are the only sites
basally phosphorylated. Biochemistry 48, 8161–8170. doi: 10.1021/bi900739f
Frontiers in Physiology | Striated Muscle Physiology August 2014 | Volume 5 | Article 315 | 10
Messer and Marston Uncoupling Ca-sensitivity from TnI phosphorylation
Bailin, G. (1979). Phosphorylation of a bovine cardiac actin complex. Am. J.
Physiol. 236, C41–C46.
Baryshnikova, O. K., Li, M. X., and Sykes, B. D. (2008). Modulation of cardiac tro-
ponin C function by the cardiac-specific N-terminus of troponin I: influence of
PKA phosphorylation and involvement in cardiomyopathies. J. Mol. Biol. 375,
735–751. doi: 10.1016/j.jmb.2007.10.062
Bayliss, C., Messer, A., Leung, M.-C., Ward, D., Van Der Velden, J., Poggesi, C.,
et al. (2012a). ∗Functional investigation of troponin with the homozygousHCM
mutation, TNNT2 K280M, obtained from an explanted heart. Cardiovasc. Res.
93, S107. doi: 10.1093/cvr/cvr336
Bayliss, C. R., Jacques, A. M., Leung, M.-C., Ward, D. G., Redwood, C. S., Gallon,
C. E., et al. (2012b). Myofibrillar Ca2+-sensitivity is uncoupled from troponin i
phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal
troponin T. Cardiovasc. Res. 97, 500–508. doi: 10.1093/cvr/cvs322
Biesiadecki, B. J., Kobayashi, T., Walker, J. S., John Solaro, R., and De Tombe, P.
P. (2007). The troponin C G159D mutation blunts myofilament desensitization
induced by troponin I Ser23/24 phosphorylation.Circ. Res. 100, 1486–1493. doi:
10.1161/01.RES.0000267744.92677.7f
Bodor, G. S., Oakeley, A. E., Allen, P. D., Crimmins, D. L., Ladenson, J. H., and
Anderson, P. A.W. (1997). Troponin I phosphorylation in the normal and failing
adult human heart. Circulation 96, 1495–1500. doi: 10.1161/01.CIR.96.5.1495
Borow, K. M., Lang, R. M., Neumann, A., Carroll, J. D., and Rajfer, S. I.
(1988). Physiologic mechanisms governing hemodynamic responses to posi-
tive inotropic therapy in patients with dilated cardiomyopathy. Circulation 77,
625–637. doi: 10.1161/01.CIR.77.3.625
Botten, D., Fugallo, G., Fraternali, F., and Molteni, C. (2013). A compu-
tational exploration of the interactions of the green tea polyphenol (-)-
epigallocatechin 3-gallate with cardiac muscle troponin C. PLoS ONE 8:e70556.
doi: 10.1371/journal.pone.0070556
Carballo, S., Robinson, P., Otway, R., Fatkin, D., Jongbloed, J. D., De Jonge, N., et al.
(2009). Identification and functional characterization of cardiac troponin I as a
novel disease gene in autosomal dominant dilated cardiomyopathy. Circ. Res.
105, 375–382. doi: 10.1161/CIRCRESAHA.109.196055
Carrier, L., Knoll, R., Vignier, N., Keller, D. I., Bausero, P., Prudhon, B., et al.
(2004). Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice.
Cardiovasc. Res. 63, 293–304. doi: 10.1016/j.cardiores.2004.04.009
Champion, H. C. (2005). Targeting protein phosphatase 1 in heart failure. Circ. Res.
96, 708–710. doi: 10.1161/01.RES.0000164359.95588.25
Chang, A. N., and Potter, J. D. (2005). Sarcomeric protein mutations in
dilated cardiomyopathy. Heart Fail. Rev. 10, 225–235. doi: 10.1007/s10741-005-
5252-6
Copeland, O., Nowak, K., Laing, N., Ravenscroft, G., Messer, A. E., Bayliss, C. R.,
et al. (2010a). Investigation of changes in skeletal muscle alpha-actin expression
in normal and pathological human and mouse hearts. J. Mus. Res. Cell. Motil.
31, 207–214. doi: 10.1007/s10974-010-9224-7
Copeland, O., Sadayappan, S., Messer, A. E., Stienen, G. J., Velden, J., and
Marston, S. B. (2010b). Analysis of cardiac myosin binding protein-C phos-
phorylation in human heart muscle. J. Mol. Cell. Cardiol. 49, 1003–1011. doi:
10.1016/j.yjmcc.2010.09.007
Deng, Y., Schmidtmann, A., Kruse, S., Filatov, V., Heilmeyer, L. M. Jr., Jaquet,
K., et al. (2003). Phosphorylation of human cardiac troponin I G203S and
K206Q linked to familial hypertrophic cardiomyopathy affects actomyosin
interaction in different ways. J. Mol. Cell. Cardiol. 35, 1365–1374. doi:
10.1016/j.yjmcc.2003.08.003
Deng, Y., Schmidtmann, A., Redlich, A., Westerdorf, B., Jaquet, K., and Thieleczek,
R. (2001). Effects of phosphorylation and mutation R145G on human
cardiac troponin I function. Biochemistry 40, 14593–14602. doi: 10.1021/
bi0115232
Dohet, C., Al-Hillawi, E., Trayer, I. P., and Ruegg, J. C. (1995). Reconstitution of
skinned cardiac fibres with human recombinant cardiac troponin-Imutants and
troponin-C. FEBS Lett. 377, 131–134. doi: 10.1016/0014-5793(95)01319-9
Dong, W. J., Jayasundar, J. J., An, J., Xing, J., and Cheung, H. C. (2007). Effects of
PKA phosphorylation of cardiac troponin I and strong crossbridge on confor-
mational transitions of the N-domain of cardiac troponin C in regulated thin
filaments. Biochemistry 46, 9752–9761. doi: 10.1021/bi700574n
Dong, W., Xing, J., Ouyang, Y., An, J., and Cheung, H. C. (2008). Structural kinet-
ics of Cardiac troponin C mutants linked to familial hypertrophic and dilated
cardiomyopathy in troponin complexes. J. Biol. Chem. 283, 3424–3432. doi:
10.1074/jbc.M703822200
Du, C. K., Morimoto, S., Nishii, K., Minakami, R., Ohta, M., Tadano, N., et al.
(2007). Knock-in mouse model of dilated cardiomyopathy caused by troponin
mutation. Circ. Res. 101, 185–194. doi: 10.1161/CIRCRESAHA.106.146670
Dubois-Randé, J. L., Merlet, P., Roudot, F., Benvenuti, C., Adnot, S., Hittinger,
L., et al. (1992). Beta-adrenergic contractile reserve as a predictor of clinical
outcome in patients with idiopathic dilated cardiomyopathy. Am. Heart J. 124,
679–685. doi: 10.1016/0002-8703(92)90278-4
Dyer, E., Jacques, A., Hoskins, A., Ward, D., Gallon, C., Messer, A., et al. (2009).
Functional analysis of a unique troponin C mutation, Gly159Asp that causes
familial dilated cardiomyopathy, studied in explanted heart muscle. Circ. Heart
Fail.2, 456–464. doi: 10.1161/CIRCHEARTFAILURE.108.818237
Dyer, E., Wells, D., Redwood, C., and Marston, S. B. (2007). ∗In vitro motility
studies of HCM and DCM mutations in cardiac muscle actin. Biophys. J. 92,
481A.
El-Armouche, A., Pohlmann, L., Schlossarek, S., Starbatty, J., Yeh, Y. H., Nattel,
S., et al. (2007). Decreased phosphorylation levels of cardiac myosin-binding
protein-C in human and experimental heart failure. J. Mol. Cell. Cardiol. 43,
223–229. doi: 10.1016/j.yjmcc.2007.05.003
England, P. J. (1976). Studies on the phosphorylation of the inhibitory subunit of
troponin during modification of contraction in perfused rat heart. Biochem. J.
160, 295–304.
Feng, W., Hwang, H. S., Kryshtal, D. O., Yang, T., Padilla, I. T., Tiwary, A. K.,
et al. (2012). Coordinated regulation of murine cardiomyocyte contractility by
nanomolar (-)-epigallocatechin-3-gallate, the major green tea catechin. Mol.
Pharmacol. 82, 993–1000. doi: 10.1124/mol.112.079707
Fentzke, R. C., Buck, S. H., Patel, J. R., Lin, H., Wolska, B. M., Stojanovic, M.
O., et al. (1999). Impaired cardiomyocyte relaxation and diastolic function in
transgenic mice expressing slow skeletal troponin I in the heart. J. Physiol. 517,
143–157. doi: 10.1111/j.1469-7793.1999.0143z.x
Ferrieres, G., Pugniere, M., Mani, J. C., Villard, S., Laprade, M., Doutre, P., et al.
(2000). Systematic mapping of regions of human cardiac troponin I involved
in binding to cardiac troponin C: N- and C-terminal low affinity contributing
regions. FEBS Lett. 479, 99–105. doi: 10.1016/S0014-5793(00)01881-0
Gallon, C., Jacques, A., Messer, A., Tsang, V., McKenna, W., andMarston, S. (2007).
∗Altered functions and post-translational modification of contractile proteins
in myectomy samples from HOCM patients. J. Mol. Cell. Cardiol. 42, S167. doi:
10.1016/j.yjmcc.2007.03.437
Gomes, A. V., Harada, K., and Potter, J. D. (2005). A mutation in the N-terminus
of troponin I that is associated with hypertrophic cardiomyopathy affects the
Ca(2+)-sensitivity, phosphorylation kinetics and proteolytic susceptibility of
troponin. J. Mol. Cell. Cardiol. 39, 754–765. doi: 10.1016/j.yjmcc.2005.05.013
Gordon, A. M., Homsher, E., and Regnier, M. (2000). Regulation of contraction in
striated muscle. Physiol. Rev. 80, 853–924.
Gould, I., Messer, A. E., Papadaki, M., and Marston, S. B. (2014). ∗Modulation
of the interaction between troponin I N-terminal peptide and troponin C by
phosphorylation studied by molecular dynamics. Biophys. J. 106, 349a.
Gramlich, M., Michely, B., Krohne, C., Heuser, A., Erdmann, B., Klaassen, S., et al.
(2009). Stress-induced dilated cardiomyopathy in a knock-in mouse model
mimicking human titin-based disease. J. Mol. Cell. Cardiol. 47, 352–358. doi:
10.1016/j.yjmcc.2009.04.014
Guinto, P. J., Haim, T. E., Dowell-Martino, C. C., Sibinga, N., and Tardiff, J.
C. (2009). Temporal and mutation-specific alterations in Ca2+ homeosta-
sis differentially determine the progression of cTnT-related cardiomyopathies
in murine models. Am. J. Physiol. Heart Circ. Physiol. 297, H614–H626. doi:
10.1152/ajpheart.01143.2008
Hamdani, N., De Waard, M., Messer, A. E., Boontje, N. M., Kooij, V., Van Dijk,
S., et al. (2009). Myofilament dysfunction in cardiac disease from mice to men.
J. Musc. Res. Cell. Motil 29, 189–201. doi: 10.1007/s10974-008-9160-y
Haworth, R. S., Cuello, F., Herron, T. J., Franzen, G., Kentish, J. C., Gautel, M.,
et al. (2004). Protein kinase D is a novel mediator of cardiac troponin I phos-
phorylation and regulates myofilament function. Circ. Res. 95, 1091–1099. doi:
10.1161/01.RES.0000149299.34793.3c
Houser, S. R., and Margulies, K. B. (2003). Is depressed myocyte con-
tractility centrally involved in heart failure? Circ. Res. 92, 350–358. doi:
10.1161/01.RES.0000060027.40275.A6
Howarth, J. W., Meller, J., Solaro, R. J., Trewhella, J., and Rosevear, P. R. (2007).
Phosphorylation-dependent conformational transition of the cardiac specific
N-extension of troponin I in cardiac troponin. J. Mol. Biol. 373, 706–722. doi:
10.1016/j.jmb.2007.08.035
www.frontiersin.org August 2014 | Volume 5 | Article 315 | 11
Messer and Marston Uncoupling Ca-sensitivity from TnI phosphorylation
Inoue, T., Kobirumaki-Shimozawa, F., Kagemoto, T., Fujii, T., Terui, T., Kusakari,
Y., et al. (2013). Depressed Frank-Starling mechanism in the left ventricu-
lar muscle of the knock-in mouse model of dilated cardiomyopathy with
troponin T deletion mutation K210. J. Mol. Cell. Cardiol. 63, 69–78. doi:
10.1016/j.yjmcc.2013.07.001
Jacques, A., Briceno, N., Messer, A., Gallon, C., Jalizadeh, S., Garcia, E., et al.
(2008). The molecular phenotype of human cardiac myosin associated with
hypertrophic obstructive cardiomyopathy. Cardiovasc. Res. 79, 481–491. doi:
10.1093/cvr/cvn094
Jacques, A., Hoskins, A., Kentish, J., and Marston, S. B. (2009). From genotype to
phenotype: a longitudinal study of a patient with hypertrophic cardiomyopathy
due to a mutation in the MYBPC3 gene. J. Musc. Res. Cell. Motil. 29, 239–246.
doi: 10.1007/s10974-009-9174-0
Javadpour, M. M., Tardiff, J. C., Pinz, I., and Ingwall, J., S. (2003). Decreased
energetics in murine hearts bearing the R92Q mutation in cardiac troponin T.
J. Clin. Invest. 112, 768–775. doi: 10.1172/JCI15967
Jweied, E., Detombe, P., and Buttrick, P. M. (2007). The use of human cardiac tissue
in biophysical research: the risks of translation. J. Mol. Cell. Cardiol. 42, 722–726.
doi: 10.1016/j.yjmcc.2007.02.002
Kaski, J. P., Burch, M., and Elliott, P. M. (2007). Mutations in the cardiac Troponin
C gene are a cause of idiopathic dilated cardiomyopathy in childhood. Cardiol.
Young 17, 675–677. doi: 10.1017/S1047951107001291
Keane, A. M., Trayer, I. P., Levine, B. A., Zeugner, C., and Ruegg, C. J. (1990).
Peptide mimetics of an actin-binding site on myosin span two functional
domains on actin. Nature 344, 265–268. doi: 10.1038/344265a0
Kentish, J. C., McCloskey, D. T., Layland, J., Palmer, S., Leiden, J. M., Martin, A.
F., et al. (2001). Phosphorylation of troponin I by protein kinase A accelerates
relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ. Res.
88, 1059–1065. doi: 10.1161/hh1001.091640
Kinoshita, E., Kinoshita-Kikuta, E., Takiyama, K., and Koike, T. (2006). Phosphate-
binding tag, a new tool to visualize phosphorylated proteins. Mol. Cell.
Proteomics 5, 749–757. doi: 10.1074/mcp.T500024-MCP200
Knoell, R., Kostin, S., Klede, S., Savvatis, K., Klinge, L., Stehle, I., et al. (2010).
A commonMLP (muscle LIM protein) variant is associated with cardiomyopa-
thy. Circ. Res. 106, 695–704. doi: 10.1161/CIRCRESAHA.109.206243
Knoell, R., Linke, W. A., Zou, P., Miocic, S., Kostin, S., Buyandelger, B.,
et al. (2011). Telethonin deficiency is associated with maladaptation to
biomechanical stress in the mammalian heart. Circ. Res. 109, 758–769. doi:
10.1161/CIRCRESAHA.111.245787
Knollmann, B. C., Blatt, S. A., Horton, K., De Freitas, F., Miller, T., Bell, M.,
et al. (2001). Inotropic stimulation induces cardiac dysfunction in transgenic
mice expressing a troponin T (I79N) mutation linked to familial hypertrophic
cardiomyopathy. J. Biol. Chem. 276, 10039–10048. doi: 10.1074/jbc.M006
745200
Kobayashi, T., Yang, X., Walker, L. A., Van Breemen, R. B., and Solaro, R. J. (2005).
A non-equilibrium isoelectric focusing method to determine states of phospho-
rylation of cardiac troponin I: identification of Ser-23 and Ser-24 as significant
sites of phosphorylation by protein kinase C. J. Mol. Cell. Cardiol. 38, 213–218.
doi: 10.1016/j.yjmcc.2004.10.014
Kooij, V., Saes, M., Jaquet, K., Zaremba, R., Foster, D. B., Murphy, A., et al. (2010).
Effect of troponin I Ser23/24 phosphorylation on Ca2+-sensitivity in human
myocardium depends on the phosphorylation background. J. Mol. Cell. Cardiol.
48, 954–963. doi: 10.1016/j.yjmcc.2010.01.002
Layland, J., Solaro, R. J., and Shah, A. M. (2005). Regulation of cardiac contrac-
tile function by troponin I phosphorylation. Cardiovasc. Res. 66, 12–21. doi:
10.1016/j.cardiores.2004.12.022
Li, A. Y., Stevens, C. M., Liang, B., Rayani, K., Little, S., Davis, J., et al.
(2013). Familial hypertrophic cardiomyopathy related cardiac troponin C L29Q
mutation alters length-dependent activation and functional effects of phos-
phomimetic troponin I∗. PLoS ONE 8:e79363. doi: 10.1371/journal.pone.
0079363
Li, M. X., Robertson, I. M., and Sykes, B. D. (2008). Interaction of cardiac tro-
ponin with cardiotonic drugs: a structural perspective. Biochem. Biophys. Res.
Commun. 369, 88–99. doi: 10.1016/j.bbrc.2007.12.108
Liu, B., Tikunova, S. B., Kline, K. P., Siddiqui, J. K., and Davis, J. P. (2012). Disease-
related cardiac troponins alter thin filament Ca2+ association and dissociation
rates. PLoS ONE 7:e38259. doi: 10.1371/journal.pone.0038259
Macleod, K. T., Marston, S. B., Poole-Wilson, P. A., Severs, N. J., and Sugden, P. H.
(2010). “Cardiac myocytes and the cardiac action potential,” inOxford Textbook
of Medicine, 5th Edn. eds D. A. Warrel, T. M. Cox, and J. D. Firth (Oxford, UK:
Oxford University Press), 2603–2617.
Mamidi, R., Gollapudi, S. K., Mallampalli, S. L., and Chandra, M. (2012). Alanine
or aspartic acid substitutions at serine23/24 of cardiac troponin I decrease thin
filament activation, with no effect on crossbridge detachment kinetics. Arch.
Biochem. Biophys. 525, 1–8. doi: 10.1016/j.abb.2012.05.024
Manning, E. P., Tardiff, J. C., and Schwartz, S. D. (2011). A model of cal-
cium activation of the cardiac thin filament. Biochemistry 50, 7405–7413. doi:
10.1021/bi200506k
Marston, S. B. (2011). How do mutations in contractile proteins cause the pri-
mary familial cardiomyopathies? J. Cardiovasc. Transl. Res. 4, 245–255. doi:
10.1007/s12265-011-9266-2
Marston, S. B., Copeland, O. A. N., and Messer, A. (2012). ∗Pressure overload is
associated with low levels of troponin I and myosin binding protein C phos-
phorylation in the hearts of patients with aortic stenosis. Circulation 126,
A14155.
Marston, S. B., Song, W., Wilkinson, R., and Vikhorev, P. G. (2013). DCM-causing
mutation ACTC E361G blunts responses to adrener- gic agonists, reduces car-
diac reserve and predispose to heart failure under chronic stress in a transgenic
mouse model. J. Mol. Cell. Cardiol. 65, s108. doi: 10.1016/j.vjmcc.2013.10.011
Marston, S. B., and Walker, J. W. (2009). Back to the future: new techniques show
that forgotten phosphorylation sites are present in contractile proteins of the
heart whilst intensively studied sites appear to be absent. J. Mus. Res. Cell. Motil.
30, 93–95. doi: 10.1007/s10974-009-9184-y
Marston, S., and Detombe, P. (2008). Point/Counterpoint. Troponin phosphoryla-
tion and myofilament Ca2+-sensitivity in heart failure: increased or decreased?
J. Mol. Cell. Cardiol. 45, 603–607. doi: 10.1016/j.yjmcc.2008.07.004
Memo, M., Leung, M.-C., Ward, D. G., Dos Remedios, C., Morimoto, S., Zhang,
L., et al. (2013). Mutations in thin filament proteins that cause familial
dilated cardiomyopathy uncouple troponin I phosphorylation from changes
in myofibrillar Ca2+-sensitivity. Cardiovasc. Res. 99, 65–73. doi: 10.1093/cvr/
cvt071
Messer, A. E., Jacques, A. M., and Marston, S. B. (2007). Troponin phosphorylation
and regulatory function in human heart muscle: dephosphorylation of Ser23/24
on troponin I could account for the contractile defect in end-stage heart failure.
J. Mol. Cell. Cardiol. 42, 247–259. doi: 10.1016/j.yjmcc.2006.08.017
Messer, A. E., Memo, M., Bayliss, C. R., Leung, M.-C., and Marston, S. B. (2012).
∗Does uncoupling of troponin I phosphorylation from changes in myofibrillar
Ca2+-sensitivity play a role in the pathogenesis of cardiomyopathy? Biophys. J.
102, 556a. doi: 10.1016/j.bpj.2011.11.3033
Messer, A. E., Papadaki, M., and Marston, S. B. (2014). ∗Effects of EMD57033 and
EGCG on Modulation of Ca2+-Sensitivity by Pka Phosphorylation. Biophys. J.
106, 726a–727a. doi: 10.1016/j.bpj.2013.11.4010
Messer, A., Gallon, C., McKenna, W., Elliott, P., Dos Remedios, C., and Marston,
S. (2009). The use of phosphate-affinity SDS-PAGE to measure the troponin I
phosphorylation site distribution in human heart muscle. Proteomics Clin. Appl.
3, 1371–1382. doi: 10.1002/prca.200900071
Mirza, M., Marston, S., Willott, R., Ashley, C., Mogensen, J., McKenna, W.,
et al. (2005). Dilated cardiomyopathy mutations in three thin filament regu-
latory proteins result in a common functional phenotype. J. Biol. Chem. 280,
28498–28506. doi: 10.1074/jbc.M412281200
Mittmann, K., Jaquet, K., and Heilmeyer, L. M. Jr. (1990). A common motif of two
adjacent phosphoserines in bovine, rabbit and human cardiac troponin I. FEBS
Lett. 273, 41–45. doi: 10.1016/0014-5793(90)81046-Q
Mogensen, J., Murphy, R. T., Shaw, T., Bahl, A., Redwood, C., Watkins, H., et al.
(2004). Severe disease expression of cardiac troponin C and T mutations
in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 44,
2033–2040. doi: 10.1016/j.jacc.2004.08.027
Moore, R. K., Grinspan, L. T., Jimenez, J., Guinto, P. J., Ertz-Berger, B., and Tardiff,
J. C. (2013). HCM-linked 160E cardiac troponin T mutation causes unique
progressive structural andmolecular ventricular remodeling in transgenic mice.
J. Mol. Cell. Cardiol. 58, 188–198. doi: 10.1016/j.yjmcc.2013.02.004
Mope, L., McClellan, G. B., and Winegrad, S. (1980). Calcium sensitivity of the
contractile system and phosphorylation of troponin in hyperpermeable cardiac
cells. J. Gen. Physiol. 75, 271–282. doi: 10.1085/jgp.75.3.271
Morimoto, S. (2008). Sarcomeric proteins and inherited cardiomyopathies.
Cardiovasc. Res. 77, 659–666. doi: 10.1093/cvr/cvm084
Naqvi, T. Z., Goel, R. K., Forrester, J. S., and Siegel, R. J. (1999). Myocardial
contractile reserve on dobutamine echocardiography predicts late spontaneous
Frontiers in Physiology | Striated Muscle Physiology August 2014 | Volume 5 | Article 315 | 12
Messer and Marston Uncoupling Ca-sensitivity from TnI phosphorylation
improvement in cardiac function in patients with recent onset idiopathic dilated
cardiomyopathy. J. Am. Coll. Cardiol. 34, 1537–1544. doi: 10.1016/S0735-
1097(99)00371-X
Nguyen, L., Chung, J., Lam, L., Tsoutsman, T., and Semsarian, C. (2007). Abnormal
cardiac response to exercise in a murine model of familial hypertrophic car-
diomyopathy. Int. J. Cardiol. 119, 245–248. doi: 10.1016/j.ijcard.2006.09.001
Nixon, B. R., Thawornkaiwong, A., Jin, J., Brundage, E. A., Little, S. C., Davis, J. P.,
et al. (2012). AMP-activated protein kinase phosphorylates cardiac troponin I at
Ser-150 to increase myofilament calcium sensitivity and blunt PKA-dependent
function. J. Biol. Chem. 287, 19136–19147. doi: 10.1074/jbc.M111.323048
Pi, Y.-Q., Kemnitz, K. R., Zhang, D., Kranias, E. G., and Walker, J. W. (2002).
Phosphorylation of troponin I controls cardiac twitch dynamics. Evidence from
phosphorylation site mutants expressed on a troponin I-null background in
mice. Circ. Res. 90, 649–656. doi: 10.1161/01.RES.0000014080.82861.5F
Pinto, J. R., Siegfried, J. D., Parvatiyar, M. S., Li, D., Norton, N., Jones, M.
A., et al. (2011). Functional characterization of TNNC1 rare variants iden-
tified in dilated cardiomyopathy. J. Biol. Chem. 286, 34404–34412. doi:
10.1074/jbc.M111.267211
Rajan, S., Ahmed, R. P., Jagatheesan, G., Petrashevskaya, N., Boivin, G. P.,
Urboniene, D., et al. (2007). Dilated cardiomyopathy mutant tropomyosin
mice develop cardiac dysfunction with significantly decreased fractional short-
ening and myofilament calcium sensitivity. Circ. Res. 101, 205–214. doi:
10.1161/CIRCRESAHA.107.148379
Ray, K. P., and England, P. J. (1976). Phosphorylation of the inhibitory subunit of
troponin and its effect on the calcium dependence of cardiac myofibril adeno-
sine triphosphatase. FEBS Lett. 70, 11–16. doi: 10.1016/0014-5793(76)80716-8
Robertson, I. M., Li, M. X., and Sykes, B. D. (2009). Solution structure
of human cardiac troponin C in complex with the green tea polyphe-
nol, (-)-epigallocatechin 3-gallate. J. Biol. Chem. 284, 23012–23023. doi:
10.1074/jbc.M109.021352
Robertson, S. P., Johnson, J. D., Holroyde, M. J., Kranias, E. G., Potter, J. D., and
Solaro, R. J. (1982). The effect of troponin I phosphorylation on the Ca2+-
binding properties of the Ca2+-regulatory site of bovine cardiac troponin.
J. Biol. Chem. 257, 260–263.
Sancho Solis, R., Ge, Y., and Walker, J. W. (2009). Single amino acid sequence
polymorphisms in rat cardiac troponin revealed by top-down tandem mass
spectrometry. J. Mus. Res. Cell. Motil. 29, 203–212. doi: 10.1007/s10974-009-
9168-y
Schmidtmann, A., Lindow, C., Villard, S., Heuser, A., Mügge, A., Gessner, R.,
et al. (2005). Cardiac troponin C-L29Q, related to hypertrophic cardiomy-
opathy, hinders the transduction of the protein kinase A dependent phospho-
rylation signal from cardiac troponin I to C. FEBS J. 272, 6087–6097. doi:
10.1111/j.1742-4658.2005.05001.x
Sequeira, V., Wijnker, P. J., Nijenkamp, L. L., Kuster, D. W., Najafi, A., Witjas-
Paalberends, E. R., et al. (2013). Perturbed length-dependent activation in
human hypertrophic cardiomyopathy with missense sarcomeric gene muta-
tions. Circ. Res. 112, 1491–1505. doi: 10.1161/CIRCRESAHA.111.300436
Solaro, R. J., Moir, A. G. J., and Perry, S. V. (1976). Phosphorylation of troponin I
and the inotropic effect of adrenaline in the perfused rabbit heart. Nature 262,
615–616. doi: 10.1038/262615a0
Solaro, R. J., Rosevear, P., and Kobayashi, T. (2008). The unique functions of cardiac
troponin I in the control of cardiac muscle contraction and relaxation. Biochem.
Biophys. Res. Commun. 369, 82–87. doi: 10.1016/j.bbrc.2007.12.114
Song, W., Dyer, E., Stuckey, D., Copeland, O., Leung, M., Bayliss, C., et al.
(2011). Molecular mechanism of the Glu99lys mutation in cardiac actin (ACTC
gene) that causes apical hypertrophy in man and mouse. J. Biol. Chem. 286,
27582–27593. doi: 10.1074/jbc.M111.252320
Song, W., Dyer, E., Stuckey, D., Leung, M.-C., Memo, M., Mansfield, C., et al.
(2010). Investigation of a transgenic mouse model of familial dilated cardiomy-
opathy. J. Mol. Cell. Cardiol. 49, 380–389. doi: 10.1016/j.yjmcc.2010.05.009
Steinberg, T. H., Agnew, B. J., Gee, K. R., Leung, W. Y., Goodman, T., Schulenberg,
B., et al. (2003). Global quantitative phosphoprotein analysis using multiplexed
proteomics technology. Proteomics 3, 1128–1144. doi: 10.1002/pmic.200300434
Stöhr, A., Friedrich, F. W., Flenner, F., Geertz, B., Eder, A., Schaaf, S., et al. (2013).
Contractile abnormalities and altered drug response in engineered heart tissue
from Mybpc3-targeted knock-in mice. J. Mol. Cell. Cardiol. 63, 189–198. doi:
10.1016/j.yjmcc.2013.07.011
Sun, N., Yazawa, M., Liu, J., Han, L., Sanchez-Freire, V., Abilez, O. J., et al.
(2012). Patient-specific induced pluripotent stem cells as a model for
familial dilated cardiomyopathy. Sci. Transl. Med. 4:130ra147. doi: 10.1126/sci-
translmed.3003552
Tadano, N., Du, C., Yumoto, F., Morimoto, S., Ohta, M., Xie, M., et al. (2010).
Biological actions of green tea catechins on cardiac troponin C. Br. J. Pharmacol.
161, 1034–1043. doi: 10.1111/j.1476-5381.2010.00942.x
Takeda, N., Yamashita, A., Maeda, K., and Maeda, Y. (2003). Structure of the core
domain of human cardiac troponin in the Ca2+-saturated form. Nature 424,
35–41. doi: 10.1038/nature01780
Van Der Velden, J., Papp, Z., Zaremba, R., Boontje, N. M., De Jong, J. W., Owen, V.
J., et al. (2003). Increased Ca2+-sensitivity of the contractile apparatus in end-
stage human heart failure results from altered phosphorylation of contractile
proteins. Cardiovasc. Res. 57, 37–47. doi: 10.1016/S0008-6363(02)00606-5
Vikhorev, S. W., Wilkinson, R., Copeland, O. A. N., Messer, A. E., Ferenczi, M. A.,
and Marston, S. B. (2013). Modulation of cardiac myofibril Ca2+-sensitivity by
phosphorylation, sarcomere length and a DCM-causing mutation. Biophys. J.
Rev. 104, 312a. doi: 10.1016/j.bpj.2012.11.1730
Wang, Y., Pinto, J. R., Solis, R. S., Dweck, D., Liang, J., Diaz-Perez, Z., et al. (2012).
Generation and functional characterization of knock-in mice harboring the car-
diac troponin I-R21C mutation associated with hypertrophic cardiomyopathy.
J. Biol. Chem. 287, 2156–2167. doi: 10.1074/jbc.M111.294306
Wang, Y., Pinto, J., Sancho Solis, R., Dweck, D., Liang, J., Diaz-Perez, Z., et al.
(2011). The generation and functional characterization of knock in mice har-
boring the cardiac Troponin I-R21C mutation associated with hypertrophic
cardiomyopathy. J. Biol. Chem. 287, 2156–2167. doi: 10.1074/jbc.M111.294306
Ward, D. G., Brewer, S. M., Calvert, M. J., Gallon, C. E., Gao, Y., and Trayer, I. P.
(2004a). Characterization of the interaction between the N-terminal extension
of human cardiac troponin I and troponin C. Biochemistry 43, 4020–4027. doi:
10.1021/bi036128l
Ward, D. G., Brewer, S. M., Gallon, C. E., Gao, Y., Levine, B. A., and
Trayer, I. P. (2004b). NMR and mutagenesis studies on the phosphoryla-
tion region of human cardiac troponin I. Biochemistry 43, 5772–5781. doi:
10.1021/bi036310m
Wilkinson, R. (2014). An Investigation Into the Disease Causing Mechanism in
Familial Dilated Cardiomyopathy. Ph.D., Imperial College, London.
Wolff, M. R., Whitesell, L. F., and Moss, R. L. (1995). Calcium sensitivity of iso-
metric tension is increased in canine experimental heart failure. Circ. Res. 76,
781–789. doi: 10.1161/01.RES.76.5.781
Yasuda, S., Coutu, P., Sadayappan, S., Robbins, J., andMetzger, J. M. (2007). Cardiac
transgenic and gene transfer strategies converge to support an important role for
troponin I in regulating relaxation in cardiac myocytes. Circ. Res. 101, 377–386.
doi: 10.1161/CIRCRESAHA.106.145557
Zabrouskov, V., Ge, Y., Schwartz, J., andWalker, J. W. (2008). Unraveling molecular
complexity of phosphorylated human cardiac troponin I by top down electron
capture dissociation/electron transfer dissociationmass spectrometry.Mol. Cell.
Proteomics 7, 1838–1849. doi: 10.1074/mcp.M700524-MCP200
Zaremba, R., Merkus, D., Hamdani, N., Lamers, J., Paulus, W., Dos Remedios,
C., et al. (2007). Quantitative analysis of myofilament protein phosphory-
lation in small cardiac biopsies. Proteomics Clin. Appl. 1, 1285–1290. doi:
10.1002/prca.200600891
Zhang, R., Zhao, J., Mandveno, A., and Potter, J. D. (1995). Cardiac troponin I
phosphorylation increases the rate of cardiac muscle relaxation. Biophys. J. 76,
1028–1035.
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 20 June 2014; accepted: 02 August 2014; published online: 25 August 2014.
Citation: Messer AE and Marston SB (2014) Investigating the role of uncoupling
of troponin I phosphorylation from changes in myofibrillar Ca2+-sensitivity in the
pathogenesis of cardiomyopathy. Front. Physiol. 5:315. doi: 10.3389/fphys.2014.00315
This article was submitted to Striated Muscle Physiology, a section of the journal
Frontiers in Physiology.
Copyright © 2014 Messer and Marston. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org August 2014 | Volume 5 | Article 315 | 13
